27/11/2025
U.S. FDA Approves Reformulated Ranitidine ✅
After a five-year pause, a newly reformulated version of ranitidine has received U.S. FDA clearance, marking its return to the U.S. market.
🔬 What’s important to know:
• NDMA-related safety concerns have been addressed
• Same therapeutic effectiveness maintained
• Indicated for GERD, peptic ulcers & Zollinger-Ellison syndrome
• Updated storage instructions for patient safety
📌 Patients using other acid-reducing medicines should consult a healthcare professional before switching.
This milestone highlights continued progress in pharmaceutical safety and formulation science.
